ALT
Altimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.42
+5.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 31.0K | 41.0K | 20.0K | 426.0K | (68.0K) |
| Cost of Revenue | 15.0M | — | — | — | — |
| Gross Profit | (15.0M) | 41.0K | 20.0K | 426.0K | (68.0K) |
| Operating Expenses | |||||
| R&D Expense | 68.2M | 66.4M | 82.2M | 65.8M | 70.5M |
| SG&A Expense | 32.0M | 28.1M | 21.0M | 18.1M | 17.1M |
| General & Admin Expense | 32.0M | 28.1M | 21.0M | 18.1M | 17.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (15.0M) | — | — | 12.4M | — |
| Total Operating Expenses | 85.3M | 94.5M | 103.2M | 96.4M | 87.7M |
| Cost and Expenses | 100.3M | 94.5M | 103.2M | 96.4M | 87.7M |
| Operating Income (EBIT) | (100.2M) | (94.5M) | (103.2M) | (95.9M) | (87.7M) |
| Non-Operating | |||||
| Interest Income | 12.3M | 7.5M | 8.1M | 7.4M | 2.9M |
| Interest Expense | 3.5M | 1.6M | 9.0K | 35.0K | 8.0K |
| Net Interest Income | 8.8M | 5.9M | 8.1M | 7.3M | 2.9M |
| Other Non-Op Income/Expense | 8.5M | 5.7M | 8.1M | 7.5M | 2.8M |
| Non-Operating Income (excl Interest) | (7.5M) | (7.4M) | (8.1M) | (7.5M) | (2.8M) |
| EBT (Pre-Tax Income) | (91.8M) | (88.8M) | (95.1M) | (88.4M) | (84.9M) |
| Income Tax Expense | — | (681.0K) | — | — | (197.0K) |
| Bottom Line | |||||
| Net Income | (91.8M) | (88.1M) | (95.1M) | (88.4M) | (84.7M) |
| Earnings from Cont. Ops | (91.8M) | (88.1M) | (95.1M) | (88.4M) | (84.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (91.8M) | (88.1M) | (95.1M) | (88.4M) | (84.7M) |
| Per Share | |||||
| Basic EPS | ($0.78) | ($1.00) | ($1.34) | ($1.66) | ($1.81) |
| Diluted EPS | ($0.78) | ($1.00) | ($1.34) | ($1.66) | ($1.81) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.01 | ($0.00) |
| Shares | |||||
| Basic Shares Outstanding | 185.4M | 88.1M | 71.0M | 53.2M | 46.9M |
| Diluted Shares Outstanding | 185.4M | 88.1M | 71.0M | 53.2M | 46.9M |
| Profitability Metrics | |||||
| EBITDA | (92.6M) | (87.0M) | (94.8M) | (87.9M) | (84.4M) |
| D&A | 99.0K | 112.0K | 238.0K | 477.0K | 493.0K |
| EBIT | (92.7M) | (87.1M) | (95.0M) | (88.4M) | (84.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026